Genprex Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:3em;'>GNP</div>
GNPX -- USA Stock  

USD 3.78  0.09  2.33%

The stock experiences an active upward rally. Genprex Net Cash Flow from Financing is fairly stable at the moment as compared to the past year. Genprex reported Net Cash Flow from Financing of 1.27 Million in 2019. Total Assets is likely to rise to about 3.8 M in 2020, whereas Average Assets are likely to drop slightly above 5.2 M in 2020. While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to break down Genprex as an investment alternative.
Published over a month ago
View all stories for Genprex | View All Stories
Will Genprex (NASDAQ:GNPX) continue to grow in September?
Debt to Equity Ratio is likely to rise to 0.17 in 2020, whereas Average Equity is likely to drop slightly above 4.7 M in 2020. On a scale of 0 to 100, Genprex holds a performance score of 7. The company retains a Market Volatility (i.e. Beta) of 0.4043, which attests to possible diversification benefits within a given portfolio. Let's try to break down what Genprex's beta means in this case. As returns on the market increase, Genprex returns are expected to increase less than the market. However, during the bear market, the loss on holding Genprex will be expected to be smaller as well. Although it is vital to follow Genprex current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-one technical indicators for Genprex, which you can use to evaluate the performance of the firm. Please utilizes Genprex coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to make a quick decision on whether Genprex current trending patterns will revert.
Genprex financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Genprex, including all of Genprex's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Genprex assets, the company is considered highly leveraged. Understanding the composition and structure of overall Genprex debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

How important is Genprex's Liquidity

Genprex financial leverage refers to using borrowed capital as a funding source to finance Genprex ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Genprex financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Genprex's total debt and its cash.

How Genprex utilizes its cash?

To perform a cash flow analysis of Genprex, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Genprex is receiving and how much cash it distributes out in a given period. The Genprex cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Genprex Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Genprex reported Net Cash Flow from Operations of (6.92 Million) in 2019

Acquisition by Varner John Rodney of 530000 shares of Genprex subject to Rule 16b-3

Legal trades by Genprex insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Genprex insider trading alert for grant of stock option (right to buy) by Varner John Rodney, President & CEO, on 25th of August 2020. This event was filed by Genprex Inc with SEC on 2020-08-25. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

Net Loss for the year was (14.06 M).

Asset Breakdown

Assets Non Current
Goodwill
3.2 M
Current Assets
Total Assets3.76 Million
Current Assets3.18 Million
Assets Non Current580,298
Goodwill439,938

Are Genprex technical ratios showing a come-back?

Current market risk adjusted performance is at 1.48. Genprex is displaying above-average volatility over the selected time horizon. Investors should scrutinize Genprex independently to ensure intended market timing strategies are aligned with expectations about Genprex volatility.

The Bottom Line

While other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Genprex may offer a potential longer-term growth to investors. To summarize, as of the 16th of August 2020, our up-to-date 30 days buy-hold-sell recommendation on the company is Hold. We believe Genprex is currently undervalued with very high probability of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Genprex. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com